Overview
CLEAR Study - A Study of CellCept (Mycophenolate Mofetil) in Recipients of Kidney Transplants
Status:
Completed
Completed
Trial end date:
2008-05-01
2008-05-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study will compare the efficacy and safety of 2 dosing regimens of oral CellCept administered as a component of standard immunosuppressive therapy in recipients of kidney transplants. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Hoffmann-La RocheTreatments:
Mycophenolate mofetil
Mycophenolic Acid
Criteria
Inclusion Criteria:- adult patients >=18 years of age;
- recipients of a primary kidney transplant.
Exclusion Criteria:
- positive for HIV-1, human T-cell leukemia/lymphoma virus-1 (HTLV-1), or hepatitis B
surface antigen;
- positive for hepatitis C virus, with moderate or severe liver disease;
- active malignancy or history of malignancy, excluding skin cancer (basal or squamous
cell) that has been adequately treated;
- need for maintenance corticosteroids for another condition.